HIV-1 proprotein processing as a target for gene therapy

P. Cordelier, Mark A Zern, D. S. Strayer

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

The central role of endoconvertases and HIV-1 protease (HIV-1 PR) in the processing of HIV proproteins makes the design of specific inhibitors important in anti-HIV gene therapy. Accordingly, we tested native α1 antitrypsin (α1AT) delivered by a recombinant simian virus-40-based vector, SV(AT), as an inhibitor of HIV-1 proprotein maturation. Cell lines and primary human lymphocytes were transduced with SV(AT) without selection and detectable toxicity. Expression of α1AT was confirmed by Northern blotting, immunoprecipitation and immunostaining. SV(AT)-transduced cells showed no evidence of HIV-1-related cytopathic effects when challenged with high doses of HIV-1NL4-3. As measured by HIV-1 p24 assay, SV(AT)-transduced cells were protected from HIV-1NL4-3 at challenge dose of 40 000 TCID50 (MOI = 0.04). In addition, peripheral blood lymphocytes treated with SV(AT) were protected from HIV doses challenge up to 40 000 TCID50 (MOI = 0.04). By Western blot analyses, the delivered α1AT inhibited cellular processing of gp 160 to gp 120 and decreased HIV-1 virion gp 120. SV(AT) inhibited processing of p55Gag as well. Furthermore, high levels of uncleaved p55Gag protein were detected in HIV virus particles recovered from SV(AT)-transduced cells lines and primary lymphocytes. Thus, delivering α1AT using SV(AT) to human lymphocytes strongly inhibits replication of HIV-1, most likely by inhibiting the activities both of the cellular serine proteases involved in processing gp160 and of the aspartyl protease, HIV-1 PR, which cleaves p55gag, α1AT delivered by SV(AT) may represent a novel and effective strategy for gene therapy to interfere with HIV replication, by blocking a stage in the virus replicative cycle that has until now been inaccessible to gene therapeutic intervention.

Original languageEnglish (US)
Pages (from-to)467-477
Number of pages11
JournalGene Therapy
Volume10
Issue number6
DOIs
StatePublished - Mar 2003

Fingerprint

Genetic Therapy
HIV-1
HIV
Lymphocytes
Virion
Aspartic Acid Proteases
Cell Line
Simian virus 40
Serine Proteases
Immunoprecipitation
Northern Blotting
Western Blotting
Viruses
Genes
Proteins

Keywords

  • α
  • Antitrypsin
  • gp160
  • p55
  • SV40

ASJC Scopus subject areas

  • Genetics

Cite this

Cordelier, P., Zern, M. A., & Strayer, D. S. (2003). HIV-1 proprotein processing as a target for gene therapy. Gene Therapy, 10(6), 467-477. https://doi.org/10.1038/sj.gt.3301891

HIV-1 proprotein processing as a target for gene therapy. / Cordelier, P.; Zern, Mark A; Strayer, D. S.

In: Gene Therapy, Vol. 10, No. 6, 03.2003, p. 467-477.

Research output: Contribution to journalArticle

Cordelier, P, Zern, MA & Strayer, DS 2003, 'HIV-1 proprotein processing as a target for gene therapy', Gene Therapy, vol. 10, no. 6, pp. 467-477. https://doi.org/10.1038/sj.gt.3301891
Cordelier, P. ; Zern, Mark A ; Strayer, D. S. / HIV-1 proprotein processing as a target for gene therapy. In: Gene Therapy. 2003 ; Vol. 10, No. 6. pp. 467-477.
@article{4f15554e7034421f8d6c9b80f1aa161b,
title = "HIV-1 proprotein processing as a target for gene therapy",
abstract = "The central role of endoconvertases and HIV-1 protease (HIV-1 PR) in the processing of HIV proproteins makes the design of specific inhibitors important in anti-HIV gene therapy. Accordingly, we tested native α1 antitrypsin (α1AT) delivered by a recombinant simian virus-40-based vector, SV(AT), as an inhibitor of HIV-1 proprotein maturation. Cell lines and primary human lymphocytes were transduced with SV(AT) without selection and detectable toxicity. Expression of α1AT was confirmed by Northern blotting, immunoprecipitation and immunostaining. SV(AT)-transduced cells showed no evidence of HIV-1-related cytopathic effects when challenged with high doses of HIV-1NL4-3. As measured by HIV-1 p24 assay, SV(AT)-transduced cells were protected from HIV-1NL4-3 at challenge dose of 40 000 TCID50 (MOI = 0.04). In addition, peripheral blood lymphocytes treated with SV(AT) were protected from HIV doses challenge up to 40 000 TCID50 (MOI = 0.04). By Western blot analyses, the delivered α1AT inhibited cellular processing of gp 160 to gp 120 and decreased HIV-1 virion gp 120. SV(AT) inhibited processing of p55Gag as well. Furthermore, high levels of uncleaved p55Gag protein were detected in HIV virus particles recovered from SV(AT)-transduced cells lines and primary lymphocytes. Thus, delivering α1AT using SV(AT) to human lymphocytes strongly inhibits replication of HIV-1, most likely by inhibiting the activities both of the cellular serine proteases involved in processing gp160 and of the aspartyl protease, HIV-1 PR, which cleaves p55gag, α1AT delivered by SV(AT) may represent a novel and effective strategy for gene therapy to interfere with HIV replication, by blocking a stage in the virus replicative cycle that has until now been inaccessible to gene therapeutic intervention.",
keywords = "α, Antitrypsin, gp160, p55, SV40",
author = "P. Cordelier and Zern, {Mark A} and Strayer, {D. S.}",
year = "2003",
month = "3",
doi = "10.1038/sj.gt.3301891",
language = "English (US)",
volume = "10",
pages = "467--477",
journal = "Gene Therapy",
issn = "0969-7128",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - HIV-1 proprotein processing as a target for gene therapy

AU - Cordelier, P.

AU - Zern, Mark A

AU - Strayer, D. S.

PY - 2003/3

Y1 - 2003/3

N2 - The central role of endoconvertases and HIV-1 protease (HIV-1 PR) in the processing of HIV proproteins makes the design of specific inhibitors important in anti-HIV gene therapy. Accordingly, we tested native α1 antitrypsin (α1AT) delivered by a recombinant simian virus-40-based vector, SV(AT), as an inhibitor of HIV-1 proprotein maturation. Cell lines and primary human lymphocytes were transduced with SV(AT) without selection and detectable toxicity. Expression of α1AT was confirmed by Northern blotting, immunoprecipitation and immunostaining. SV(AT)-transduced cells showed no evidence of HIV-1-related cytopathic effects when challenged with high doses of HIV-1NL4-3. As measured by HIV-1 p24 assay, SV(AT)-transduced cells were protected from HIV-1NL4-3 at challenge dose of 40 000 TCID50 (MOI = 0.04). In addition, peripheral blood lymphocytes treated with SV(AT) were protected from HIV doses challenge up to 40 000 TCID50 (MOI = 0.04). By Western blot analyses, the delivered α1AT inhibited cellular processing of gp 160 to gp 120 and decreased HIV-1 virion gp 120. SV(AT) inhibited processing of p55Gag as well. Furthermore, high levels of uncleaved p55Gag protein were detected in HIV virus particles recovered from SV(AT)-transduced cells lines and primary lymphocytes. Thus, delivering α1AT using SV(AT) to human lymphocytes strongly inhibits replication of HIV-1, most likely by inhibiting the activities both of the cellular serine proteases involved in processing gp160 and of the aspartyl protease, HIV-1 PR, which cleaves p55gag, α1AT delivered by SV(AT) may represent a novel and effective strategy for gene therapy to interfere with HIV replication, by blocking a stage in the virus replicative cycle that has until now been inaccessible to gene therapeutic intervention.

AB - The central role of endoconvertases and HIV-1 protease (HIV-1 PR) in the processing of HIV proproteins makes the design of specific inhibitors important in anti-HIV gene therapy. Accordingly, we tested native α1 antitrypsin (α1AT) delivered by a recombinant simian virus-40-based vector, SV(AT), as an inhibitor of HIV-1 proprotein maturation. Cell lines and primary human lymphocytes were transduced with SV(AT) without selection and detectable toxicity. Expression of α1AT was confirmed by Northern blotting, immunoprecipitation and immunostaining. SV(AT)-transduced cells showed no evidence of HIV-1-related cytopathic effects when challenged with high doses of HIV-1NL4-3. As measured by HIV-1 p24 assay, SV(AT)-transduced cells were protected from HIV-1NL4-3 at challenge dose of 40 000 TCID50 (MOI = 0.04). In addition, peripheral blood lymphocytes treated with SV(AT) were protected from HIV doses challenge up to 40 000 TCID50 (MOI = 0.04). By Western blot analyses, the delivered α1AT inhibited cellular processing of gp 160 to gp 120 and decreased HIV-1 virion gp 120. SV(AT) inhibited processing of p55Gag as well. Furthermore, high levels of uncleaved p55Gag protein were detected in HIV virus particles recovered from SV(AT)-transduced cells lines and primary lymphocytes. Thus, delivering α1AT using SV(AT) to human lymphocytes strongly inhibits replication of HIV-1, most likely by inhibiting the activities both of the cellular serine proteases involved in processing gp160 and of the aspartyl protease, HIV-1 PR, which cleaves p55gag, α1AT delivered by SV(AT) may represent a novel and effective strategy for gene therapy to interfere with HIV replication, by blocking a stage in the virus replicative cycle that has until now been inaccessible to gene therapeutic intervention.

KW - α

KW - Antitrypsin

KW - gp160

KW - p55

KW - SV40

UR - http://www.scopus.com/inward/record.url?scp=0344642957&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0344642957&partnerID=8YFLogxK

U2 - 10.1038/sj.gt.3301891

DO - 10.1038/sj.gt.3301891

M3 - Article

VL - 10

SP - 467

EP - 477

JO - Gene Therapy

JF - Gene Therapy

SN - 0969-7128

IS - 6

ER -